Somerville, MA, United States of America

Bettina Strack-Logue

This inventor holds 12 USPTO granted patents and 10 published patent applications and 7 EPO patents. Top assignees: Shire Human Genetic Therapies, Inc., Translate Bio, Inc., Takeda Pharmaceutical Company Limited. Active years: 2016-2026.

USPTO Granted Patents = 12 (Patent Applications = 10)

% Patents Active = 83.3

EPO Patents = 7 (Patent Applications = 14)

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 21(Granted Patents)

Location History:

Lexington, MA (US) (2018 - 2021)
Somerville, MA (US) (2016 - 2023)

Company Filing History:

8 out of 86

Shire Human Genetic Therapies, Inc.

Takeda Pharmaceutical Company Limited

patents

Years Active: 2016-2026

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577600 - MODIFICATION OF RNA-RELATED ENZYMES FOR ENHANCED PRODUCTION (2026-03-17),

2. 11660328 - GLP-2 analogs and peptibodies for administration before, during or after surgery (2023-05-30),

3. 11065307 - Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moiety (2021-07-20),

4. 10995354 - Modification of RNA-related enzymes for enhanced production (2021-05-04),

5. 10722559 - Mannose-6-phosphate bearing peptides fused to lysosomal enzymes (2020-07-28),

6. 10603364 - Lysosomal targeting and uses thereof (2020-03-31),

7. 10144942 - Modification of RNA-related enzymes for enhanced production (2018-12-04),

8. 9932377 - Mitochondrial targeting and therapeutic use thereof (2018-04-03),

9. 9814764 - Treatment of Sanfilippo syndrome type B by intrathecal administration of alpha-n-acetylglucosaminidase (2017-11-14),

10. 9597376 - Lipoprotein lipase for treatment of hypertriglyceridemic-related conditions including acute pancreatitis (2017-03-21),

11. 9453847 - Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof (2016-09-27),

12. 9260495 - Mitochondrial targeting and therapeutic use thereof (2016-02-16),

Title: Bettina Strack-Logue: Pioneering Innovations in Medical Therapies

Introduction:

Bettina Strack-Logue, a visionary inventor based in Somerville, MA (US), is a trailblazer in the field of medical therapies. With a passion for innovation and a relentless pursuit of excellence, she has inspired the next generation of innovators to think boldly and push the limits of what is possible.

Latest Patents:

Bettina Strack-Logue holds 11 patents, including groundbreaking inventions such as GLP-2 analogs and peptibodies for administration before, during, or after surgery. These innovations, such as teduglutide and fusion proteins of GLP-2 with immunoglobulin, have the potential to revolutionize post-surgical care, particularly in cases of short bowel syndrome.

Career Highlights:

Throughout her illustrious career, Bettina has made significant contributions to companies like Shire Human Genetic Therapies, Inc. and Translate Bio, Inc. Her innovative spirit and dedication to advancing medical therapies have garnered recognition from peers and industry leaders alike.

Collaborations:

Bettina has collaborated with esteemed professionals in the field, including coworkers Michael F Concino and Angela Norton. Together, they have worked tirelessly to develop novel solutions for complex medical challenges, leaving a lasting impact on the industry.

Conclusion:

In conclusion, Bettina Strack-Logue's unwavering commitment to innovation and her groundbreaking inventions have cemented her legacy as a visionary inventor in the field of medical therapies. Her contributions continue to inspire and shape the future of healthcare, paving the way for transformative advancements in patient care.